 | - August 23-24, 2022
- August 2022 Article Summary: Time to Positive Culture Detection Predicts Mycobacterium avium Pulmonary Disease Severity and Treatment Initiation. Ann Am Thorac Soc. 2022 Jun;19(6):925-932. doi: 10.1513/AnnalsATS.202107-765OC. PMID: 34851813. View here.
- Recorded Zoom Webinar on VuMedi.
|
| | - July 26-27, 2022
- July 2022 Article Summary: Consensus management recommendations for less common non-tuberculous mycobacterial pulmonary diseases. Lancet Infect Dis. 2022 Jul;22(7):e178-e190. doi: 10.1016/S1473-3099(21)00586-7. Epub 2022 Jan 25. Erratum in: Lancet Infect Dis. 2022 Mar;22(3):e73. PMID: 35090639. View here.
- Recorded Zoom Webinar on VuMedi.
|
| | - June 28-29, 2022
- June 2022 Article Summary: Host and pathogen response to bacteriophage engineered against Mycobacterium abscessus lung infection. Cell. 2022 May 26;185(11):1860-1874.e12. doi: 10.1016/j.cell.2022.04.024. Epub 2022 May 13. PMID: 35568033. View here.
- Recorded Zoom Webinar on VuMedi.
|
| | - May 24-25, 2022
- May 2022 Article Summary: Genomic Analysis of a Hospital-Associated Outbreak of Mycobacterium abscessus: Implications on Transmission. J Clin Microbiol. 2022 Jan 19;60(1):e0154721. doi: 10.1128/JCM.01547-21. Epub 2021 Oct 27. PubMed PMID: 34705540; PubMed Central PMCID: PMC8769749. View here.
- Recorded Zoom Webinar on VuMedi.
|
| - April 26-27, 2022
- April 2022 Article Summary: Mycobacterium abscessus biofilms have viscoelastic properties which may contribute to their recalcitrance in chronic pulmonary infections. Sci Rep. 2021 Mar 3;11(1):5020. doi: 10.1038/s41598-021-84525-x. PMID: 33658597. View here.
- Recorded Zoom Webinar on VuMedi.
|
| - March 29-30, 2022
- March 2022 Article Summary: Pilot study to test inhaled nitric oxide in cystic fibrosis patients with refractory Mycobacterium abscessus lung infection. J Cyst Fibros. 2020 Mar;19(2):225-231. doi: 10.1016/j.jcf.2019.05.002. Epub 2019 May 23. PMID: 31129068. View here.
|
| - February 22-23, 2022
- February 2022 Article Summary: Mycobacteriophage-antibiotic therapy promotes enhanced clearance of drug-resistant Mycobacterium abscessus. Matt D Johansen, Matthéo Alcaraz, Rebekah M Dedrick, Françoise Roquet-Banères, Claire Hamela, Graham F Hatfull, Laurent Kremer. s Model Mech. 2021 Sep 1;14(9):dmm049159. doi: 10.1242/dmm.049159. View here.
- Recorded Zoom Webinar on VuMedi.
|
| - January 25-26, 2022
- January 2022 Article Summary: Preliminary, Real-world, Multicenter Experience With Omadacycline for Mycobacterium abscessus Infections. Open Forum Infectious Diseases, Volume 8, Issue 2, February 2021, ofab002, https://doi.org/10.1093/ofid/ofab002. View here.
- Recorded Zoom Webinar on VuMedi.
|
| - November 30, 2021
- November 2021 Article Summary: Airway Clearance Techniques in Bronchiectasis: Analysis From the United States Bronchiectasis and Non-TB Mycobacteria Research Registry. Chest, Volume 158, Issue 4, 2020, Pages 1376-1384, ISSN 0012-3692, https://doi.org/10.1016/j.chest.2020.06.050. View here.
- Recorded Zoom Webinar on VuMedi.
|
| - October 26-27, 2021
- October 2021 Article Summary: Amikacin Liposome Inhalation Suspension for Refractory Mycobacterium avium Complex Lung Disease: Sustainability and Durability of Culture Conversion and Safety of Long-term Exposure. Griffith DE, et al; CONVERT Study Group.Chest. 2021 Sep;160(3):831-842. DOI: 10.1016/j.chest.2021.03.070. View here.
- Recorded Zoom Webinar on VuMedi.
|
| - September 28-29, 2021
- September 2021 Article Summary: Phase 2 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis, N Engl J Med 2020; 383:2127-2137, DOI: 10.1056/NEJMoa2021713. View here.
- Recorded Zoom Webinar on VuMedi.
|
| - August 24-25, 2021
- August 2021 Article Summary: Amikacin liposome inhalation suspension for Treatment-Refractory lung disease caused by Mycobacterium avium complex (CONVERT). A prospective, open-label, randomized study. Am J Repir Crit Care Med 2018; 198: 1559-1569. View here.
- Recorded Zoom Webinar on VuMedi.
|
